JP Patent

JP2024012211A — ミカファンギン組成物

Assigned to Baxter Healthcare SA · Expires 2024-01-25 · 2y expired

What this patent protects

【課題】非経口投与に適し、貯蔵安定性が増強された水性医薬組成物の提供。【解決手段】非経口投与に適し、貯蔵安定性が増強された水性医薬組成物は、約０．１ｍｇ／ｍＬ～約４０ｍｇ／ｍＬのミカファンギンと、（ｉｉ）約０．１ｍＭ～４００ｍＭの緩衝剤と、（ｉｉｉ）約０ｍｇ／ｍＬ～約５００ｍｇ／ｍＬの等張化剤と、を含み、本組成物のｐＨは約３．０～７．０、例えば約３．５～７．０である。【選択図】図１

USPTO Abstract

【課題】非経口投与に適し、貯蔵安定性が増強された水性医薬組成物の提供。【解決手段】非経口投与に適し、貯蔵安定性が増強された水性医薬組成物は、約０．１ｍｇ／ｍＬ～約４０ｍｇ／ｍＬのミカファンギンと、（ｉｉ）約０．１ｍＭ～４００ｍＭの緩衝剤と、（ｉｉｉ）約０ｍｇ／ｍＬ～約５００ｍｇ／ｍＬの等張化剤と、を含み、本組成物のｐＨは約３．０～７．０、例えば約３．５～７．０である。【選択図】図１

Drugs covered by this patent

Patent Metadata

Patent number
JP2024012211A
Jurisdiction
JP
Classification
—
Expires
2024-01-25
Drug substance claim
No
Drug product claim
No
Assignee
Baxter Healthcare SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.